OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Revenue

In the fiscal year ending June 30, 2026, OncoSil Medical had annual revenue of 5.09M AUD with 231.48% growth. OncoSil Medical had revenue of 1.91M in the half year ending June 30, 2026, with 107.00% growth. That makes OncoSil Medical the 40,989th largest company in the world by revenue and 805th in Australia.

• Revenue: 5.09M
• Revenue Growth: +231.48%
• P/S Ratio: 5.41
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 27.53M

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Europe 1.40M 83.4%
• Middle East 189.10K 11.2%
• Australia 91.36K 5.4%

Fiscal year ended Jun 30, 2026 See the full OncoSil Medical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	5.09M	3.55M	231.48%
Jun 30, 2025	1.54M	-30.12K	-1.92%
Jun 30, 2024	1.57M	97.96K	6.68%
Jun 30, 2023	1.47M	404.03K	38.00%
Jun 30, 2022	1.06M	-234.94K	-18.10%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 24, 2026

Data Sources Report a data error